Stevenson D D, Pleskow W W, Simon R A, Mathison D A, Lumry W R, Schatz M, Zeiger R S
J Allergy Clin Immunol. 1984 Apr;73(4):500-7. doi: 10.1016/0091-6749(84)90361-0.
Twenty-five ASA-sensitive patients with rhinosinusitis asthma underwent oral ASA challenges followed by desensitization to the adverse respiratory effects of ASA. We then compared the efficacy of continuous ASA treatment for their respiratory tract disease to that of a placebo treatment during a double-blind crossover study. For this group of 25 patients, there was significant improvement in nasal symptoms and a reduction in use of nasal beclomethasone during the months when they received ASA treatment. Lower respiratory tract symptoms, values of FEV1, and the use of antiasthmatic medications including prednisone were not significantly changed during ASA treatment. Desensitization to ASA followed by ASA treatment appears to significantly alleviate symptoms of rhinosinusitis. However, only half the patients experienced improvement in their asthma symptoms during ASA treatment.
25例对阿司匹林敏感的鼻窦炎哮喘患者接受了口服阿司匹林激发试验,随后对阿司匹林的不良呼吸道效应进行脱敏治疗。然后,我们在一项双盲交叉研究中比较了持续使用阿司匹林治疗其呼吸道疾病与安慰剂治疗的疗效。对于这组25例患者,在接受阿司匹林治疗的几个月里,鼻部症状有显著改善,布地奈德鼻喷雾剂的使用量减少。在阿司匹林治疗期间,下呼吸道症状、第一秒用力呼气容积(FEV1)值以及包括泼尼松在内的抗哮喘药物的使用量均无显著变化。对阿司匹林进行脱敏治疗后再使用阿司匹林似乎能显著缓解鼻窦炎症状。然而,只有一半的患者在阿司匹林治疗期间哮喘症状有所改善。